Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.

Following publication of the original article [1], it was reported that the legend for Fig. 1 was incomplete. The complete figure legend is.

Correction to: BMC Cancer

DOI 10.1186/s12885-017-3286-5

Following publication of the original article [1], it was reported that the legend for Fig. 1 was incomplete. The complete figure legend is:

Fig. 1 Swimlane plot of time to response, treatment duration, and duration of follow-up for efficacy-evaluable patients who achieved response in the mBCC cohort (a), those in the laBCC cohort with treatment duration > 20 months (b), and those in the laBCC cohort who were treated for < 20 months (c). laBCC, locally advanced basal cell carcinoma; mBCC, metastatic basal cell carcinoma.